Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.

Summary Expression Phenotypes Gene Literature (151) GO Terms (5) Nucleotides (57) Proteins (40) Interactants (234) Wiki
XB-GENEPAGE-949326

Papers associated with grin2b



???displayGene.coCitedPapers???

???pagination.result.count???

???pagination.result.page??? ???pagination.result.prev??? 1 2 3 4 ???pagination.result.next???

Sort Newest To Oldest Sort Oldest To Newest

Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission., Frizelle PA, Chen PE, Wyllie DJ., Mol Pharmacol. September 1, 2006; 70 (3): 1022-32.

A genetically modified mouse model probing the selective action of ifenprodil at the N-methyl-D-aspartate type 2B receptor., Rosahl TW, Wingrove PB, Hunt V, Fradley RL, Lawrence JM, Heavens RP, Treacey P, Usala M, Macaulay A, Bonnert TP, Whiting PJ, Wafford KA., Mol Cell Neurosci. September 1, 2006; 33 (1): 47-56.

Differential modulation of human N-methyl-D-aspartate receptors by structurally diverse general anesthetics., Solt K, Eger EI, Raines DE., Anesth Analg. May 1, 2006; 102 (5): 1407-11.

Nickel differentially affects NMDA receptor channels in developing cultured rat neurons., Gavazzo P, Mazzolini M, Tedesco M, Marchetti C., Dev Biol. March 17, 2006; 1078 (1): 71-9.

NMDA receptor subunit-dependent modulation by conantokin-G and Ala7-conantokin-G., Ragnarsson L, Yasuda T, Lewis RJ, Dodd PR, Adams DJ., J Neurochem. January 1, 2006; 96 (1): 283-91.

Tweaking agonist efficacy at N-methyl-D-aspartate receptors by site-directed mutagenesis., Hansen KB, Clausen RP, Bjerrum EJ, Bechmann C, Greenwood JR, Christensen C, Kristensen JL, Egebjerg J, Bräuner-Osborne H., Mol Pharmacol. December 1, 2005; 68 (6): 1510-23.

CaMKII tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of Ca2+ signals for facilitation., Hudmon A, Schulman H, Kim J, Maltez JM, Tsien RW, Pitt GS., J Cell Biol. November 7, 2005; 171 (3): 537-47.                

NMDA receptors as targets of heavy metal interaction and toxicity., Marchetti C, Gavazzo P., Neurotox Res. November 1, 2005; 8 (3-4): 245-58.

Multivalent interactions of calcium/calmodulin-dependent protein kinase II with the postsynaptic density proteins NR2B, densin-180, and alpha-actinin-2., Robison AJ, Bass MA, Jiao Y, MacMillan LB, Carmody LC, Bartlett RK, Colbran RJ., J Biol Chem. October 21, 2005; 280 (42): 35329-36.

Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids., Conti P, De Amici M, Grazioso G, Roda G, Pinto A, Hansen KB, Nielsen B, Madsen U, Bräuner-Osborne H, Egebjerg J, Vestri V, Pellegrini-Giampietro DE, Sibille P, Acher FC, De Micheli C., J Med Chem. October 6, 2005; 48 (20): 6315-25.

Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket., Kinarsky L, Feng B, Skifter DA, Morley RM, Sherman S, Jane DE, Monaghan DT., J Pharmacol Exp Ther. June 1, 2005; 313 (3): 1066-74.

Corymine potentiates NMDA-induced currents in Xenopus oocytes expressing NR1a/NR2B glutamate receptors., Leewanich P, Tohda M, Takayama H, Sophasan S, Watanabe H, Matsumoto K., J Pharmacol Sci. May 1, 2005; 98 (1): 58-65.

Modulation of triheteromeric NMDA receptors by N-terminal domain ligands., Hatton CJ, Paoletti P., Neuron. April 21, 2005; 46 (2): 261-74.

Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists., Morley RM, Tse HW, Feng B, Miller JC, Monaghan DT, Jane DE., J Med Chem. April 7, 2005; 48 (7): 2627-37.

PKC site mutations reveal differential modulation by insulin of NMDA receptors containing NR2A or NR2B subunits., Jones ML, Leonard JP., J Neurochem. March 1, 2005; 92 (6): 1431-8.

The effect of competitive antagonist chain length on NMDA receptor subunit selectivity., Feng B, Morley RM, Jane DE, Monaghan DT., Neuropharmacology. March 1, 2005; 48 (3): 354-9.

The micromolar zinc-binding domain on the NMDA receptor subunit NR2B., Rachline J, Perin-Dureau F, Le Goff A, Neyton J, Paoletti P., J Neurosci. January 12, 2005; 25 (2): 308-17.

Monoamines directly inhibit N-methyl-D-aspartate receptors expressed in Xenopus oocytes in a voltage-dependent manner., Masuko T, Suzuki I, Kizawa Y, Kusama-Eguchi K, Watanabe K, Kashiwagi K, Igarashi K, Kusama T., Neurosci Lett. November 16, 2004; 371 (1): 30-3.

Endocytosis and degradative sorting of NMDA receptors by conserved membrane-proximal signals., Scott DB, Michailidis I, Mu Y, Logothetis D, Ehlers MD., J Neurosci. August 11, 2004; 24 (32): 7096-109.

Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride)., Sun L, Chiu D, Kowal D, Simon R, Smeyne M, Zukin RS, Olney J, Baudy R, Lin S., J Pharmacol Exp Ther. August 1, 2004; 310 (2): 563-70.

Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus., Lozovaya NA, Grebenyuk SE, Tsintsadze TSh, Feng B, Monaghan DT, Krishtal OA., J Physiol. July 15, 2004; 558 (Pt 2): 451-63.

Anthraquinone polyamines: novel channel blockers to study N-methyl-D-aspartate receptors., Kashiwagi K, Tanaka I, Tamura M, Sugiyama H, Okawara T, Otsuka M, Sabado TN, Williams K, Igarashi K., J Pharmacol Exp Ther. June 1, 2004; 309 (3): 884-93.

A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity., Jang MK, Mierke DF, Russek SJ, Farb DH., Proc Natl Acad Sci U S A. May 25, 2004; 101 (21): 8198-8203.

Differential modulation of NR1-NR2A and NR1-NR2B subtypes of NMDA receptor by PDZ domain-containing proteins., Iwamoto T, Yamada Y, Hori K, Watanabe Y, Sobue K, Inui M., J Neurochem. April 1, 2004; 89 (1): 100-8.

Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid., Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT., Br J Pharmacol. February 1, 2004; 141 (3): 508-16.

Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket., Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, Kew JN., J Pharmacol Exp Ther. December 1, 2003; 307 (3): 897-905.

Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in xenopus oocytes in a subunit specific manner., Levine JB, Martin G, Wilson A, Treistman SN., Neurosci Lett. August 7, 2003; 346 (3): 125-8.

Structural model of the N-methyl-D-aspartate receptor glycine site probed by site-directed chemical coupling., Foucaud B, Laube B, Schemm R, Kreimeyer A, Goeldner M, Betz H., J Biol Chem. June 27, 2003; 278 (26): 24011-7.

ATP inhibits NMDA receptors after heterologous expression and in cultured hippocampal neurons and attenuates NMDA-mediated neurotoxicity., Ortinau S, Laube B, Zimmermann H., J Neurosci. June 15, 2003; 23 (12): 4996-5003.

Activation of NR1a/NR2B receptors by monocyte-derived macrophage secretory products: implications for human immunodeficiency virus type one-associated dementia., Xiong H, McCabe L, Skifter D, Monaghan DT, Gendelman HE., Neurosci Lett. May 8, 2003; 341 (3): 246-50.

Pharmacology of delta2 glutamate receptors: effects of pentamidine and protons., Williams K, Dattilo M, Sabado TN, Kashiwagi K, Igarashi K., J Pharmacol Exp Ther. May 1, 2003; 305 (2): 740-8.

Oxygen sensitivity of NMDA receptors: relationship to NR2 subunit composition and hypoxia tolerance of neonatal neurons., Bickler PE, Fahlman CS, Taylor DM., Neuroscience. January 1, 2003; 118 (1): 25-35.

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist., Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA., J Pharmacol Exp Ther. September 1, 2002; 302 (3): 940-8.

N-Methyl-D-aspartate receptor subtype-selectivity of homoquinolinate: an electrophysiological and radioligand binding study using both native and recombinant receptors., Grimwood S, Wafford KA, Macaulay A, Hutson PH., J Neurochem. August 1, 2002; 82 (4): 794-800.

Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors., Perin-Dureau F, Rachline J, Neyton J, Paoletti P., J Neurosci. July 15, 2002; 22 (14): 5955-65.

Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore., Kashiwagi K, Masuko T, Nguyen CD, Kuno T, Tanaka I, Igarashi K, Williams K., Mol Pharmacol. March 1, 2002; 61 (3): 533-45.

Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids., Malayev A, Gibbs TT, Farb DH., Br J Pharmacol. February 1, 2002; 135 (4): 901-9.

Specificity of putative partial agonist, 1-aminocyclopropanecarboxylic acid, for rat N-methyl-D-aspartate receptor subunits., Sheinin A, Nahum-Levy R, Shavit S, Benveniste M., Neurosci Lett. January 11, 2002; 317 (2): 77-80.

Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue., Ronald KM, Mirshahi T, Woodward JJ., J Biol Chem. November 30, 2001; 276 (48): 44729-35.

Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition., Wittekindt B, Malany S, Schemm R, Otvos L, Maccecchini ML, Laube B, Betz H., Neuropharmacology. November 1, 2001; 41 (6): 753-61.

Lead inhibition of NMDA channels in native and recombinant receptors., Gavazzo P, Gazzoli A, Mazzolini M, Marchetti C., Neuroreport. October 8, 2001; 12 (14): 3121-5.

Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine., Sheinin A, Shavit S, Benveniste M., Neuropharmacology. August 1, 2001; 41 (2): 151-8.

The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801., Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgänsberger W, Schadrack J., Neuropharmacology. May 1, 2001; 40 (6): 749-60.

Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current., Liao GY, Wagner DA, Hsu MH, Leonard JP., Mol Pharmacol. May 1, 2001; 59 (5): 960-4.

K(+) occupancy of the N-methyl-d-aspartate receptor channel probed by Mg(2+) block., Zhu Y, Auerbach A., J Gen Physiol. March 1, 2001; 117 (3): 287-98.            

Na(+) occupancy and Mg(2+) block of the n-methyl-d-aspartate receptor channel., Zhu Y, Auerbach A., J Gen Physiol. March 1, 2001; 117 (3): 275-86.              

Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits., Coughenour LL, Barr BM., J Pharmacol Exp Ther. January 1, 2001; 296 (1): 150-9.

Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors., Donevan SD, McCabe RT., Mol Pharmacol. September 1, 2000; 58 (3): 614-23.

Modulation of hypothalamic NMDA receptor function by cyclic AMP-dependent protein kinase and phosphatases., Nijholt I, Blank T, Liu A, Kügler H, Spiess J., J Neurochem. August 1, 2000; 75 (2): 749-54.

In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus., White HS, McCabe RT, Armstrong H, Donevan SD, Cruz LJ, Abogadie FC, Torres J, Rivier JE, Paarmann I, Hollmann M, Olivera BM., J Pharmacol Exp Ther. January 1, 2000; 292 (1): 425-32.

???pagination.result.page??? ???pagination.result.prev??? 1 2 3 4 ???pagination.result.next???